Clinical Trials Logo

Personality Disorders clinical trials

View clinical trials related to Personality Disorders.

Filter by:

NCT ID: NCT00358969 Recruiting - Clinical trials for Borderline Personality Disorder

Guanfacine to Treat Borderline Personality Disorder

Start date: July 2006
Phase: N/A
Study type: Interventional

This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.

NCT ID: NCT00255554 Recruiting - Clinical trials for Borderline Personality Disorder

DBT and Escitalopram in Borderline Personality Disorder

Start date: n/a
Phase: N/A
Study type: Interventional

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

NCT ID: NCT00252044 Recruiting - Clinical trials for Schizotypal Personality Disorder

Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

Start date: October 2000
Phase: N/A
Study type: Interventional

Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance on the cognitive tasks, with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo. Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed by pergolide for four weeks.

NCT ID: NCT00252031 Recruiting - Clinical trials for Borderline Personality Disorder

DBT in Borderline Personality Disorder

Start date: n/a
Phase: N/A
Study type: Interventional

Subjects will receive a 6-month course of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist.

NCT ID: NCT00060788 Recruiting - Clinical trials for Antisocial Personality Disorder

Antisocial Behavior: Passing From Parent to Child to Grandchild

Start date: September 2001
Phase: N/A
Study type: Observational

Antisocial behavior often occurs in different generations within the same family. However, it is not known what factors contribute to this passing of antisocial behavior from parent to child to grandchild. This study is part of a project evaluating antisocial behavior in families; it focuses on the passage of such behavior from one generation to the next.